Trial Profile
Postmarketing Study to Assess the Safety of Nivolumab as a First- and Second-line Treatment in Patients With Metastatic Melanoma or as a Second-line Treatment for Metastatic Lung Cancer (Squamous and Nonsquamous), Metastatic Renal Cancer, Squamous Cell Carcinoma of the Head and Neck, and Chronic Hodgkin Lymphoma in Adult Patients in Mexico
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 30 May 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Head and neck cancer; Hodgkin's disease; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Squamous cell cancer
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 25 May 2022 Status changed from recruiting to withdrawn prior to enrolment.
- 15 Aug 2017 Status changed from not yet recruiting to recruiting.
- 12 Jun 2017 Planned initiation date changed from 16 Jun 2017 to 31 Jul 2017.